{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:01:10Z","timestamp":1740146470993,"version":"3.37.3"},"reference-count":19,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:00:00Z","timestamp":1546992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0210384","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T18:52:18Z","timestamp":1547059938000},"page":"e0210384","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6379-2947","authenticated-orcid":true,"given":"Naho","family":"Kuroishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asuka","family":"Watananbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuta","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Ruzicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuyoshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,1,9]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/QAI.0b013e3181b064b0","article-title":"Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-na\u00efve patients with HIV-1 infection","volume":"52","author":"M Markowitz","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/QAI.0b013e3181c9c967","article-title":"Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study","volume":"53","author":"JM Gatell","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"RT Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1086\/650002","article-title":"Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials","volume":"50","author":"RT Steigbigel","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1473-3099(13)70093-8","article-title":"Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials","volume":"13","author":"JJ Eron","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"9692","key":"ref6","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-na\u00efve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"JL Lennox","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e3181da1287","article-title":"Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses","volume":"55","author":"JL Lennox","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","article-title":"Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-na\u00efve HIV-1-infected patients: final 5-year results from STARTMRK","volume":"63","author":"JK Rockstroh","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"journal-title":"Merck receives FDA Approval of ISENTRESS HD (raltegravir), a new once-daily option, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in appropriate patients","article-title":"Merck receives FDA Approval of ISENTRESS HD (raltegravir), a new once-daily option, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in appropriate patients","key":"ref9"},{"unstructured":"Annual Report on AIDS Trends 2016, AIDS Surveillance Committee, Ministry of Health, Labour and Welfare. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/api-net.jfap.or.jp\/status\/2016\/16nenpo\/16nenpo_menu.html\" xlink:type=\"simple\">http:\/\/api-net.jfap.or.jp\/status\/2016\/16nenpo\/16nenpo_menu.html<\/ext-link>","key":"ref10"},{"unstructured":"HIV-related drug co-operative survey. HRD website. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.hrd.gr.jp\/index.html\" xlink:type=\"simple\">https:\/\/www.hrd.gr.jp\/index.html<\/ext-link>.","key":"ref11"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1310\/hct1102-110","article-title":"Twelve-year experience of nevirapine use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients","volume":"11","author":"V Reliquet","year":"2010","journal-title":"HIV Clin Trials"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-3156.2010.02690.x","article-title":"Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal","volume":"16","author":"C Laurent","year":"2011","journal-title":"Trop Med Int Health"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"20773","DOI":"10.7448\/IAS.19.1.20773","article-title":"First-line antiretroviral therapy durability in a 10-year cohort of na\u00efve adults started on treatment in Uganda","volume":"19","author":"B Castelnuovo","year":"2016","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1310\/hct0901-1","article-title":"Seven-year efficacy of a lopinavir\/ritonavir-based regimen in antiretroviral-na\u00efve HIV-1-infected patients","volume":"9","author":"RL Murphy","year":"2008","journal-title":"HIV Clin Trials"},{"key":"ref16","first-page":"1","article-title":"1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"41","year":"1992","journal-title":"MMWR Recomm Rep"},{"unstructured":"Assessment Report for Isentress tablet 400 mg. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.pmda.go.jp\/drugs\/2008\/P200800025\/63015300_22000AMX01647_A100_1.pdf\" xlink:type=\"simple\">http:\/\/www.pmda.go.jp\/drugs\/2008\/P200800025\/63015300_22000AMX01647_A100_1.pdf<\/ext-link>.","key":"ref17"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijantimicag.2014.10.013","article-title":"Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance","volume":"45","author":"G Madeddu","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"18","key":"ref19","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1097\/QAD.0b013e32835aa141","article-title":"Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study","volume":"26","author":"G Madeddu","year":"2012","journal-title":"AIDS"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0210384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T07:55:48Z","timestamp":1589010948000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0210384"}},"subtitle":[],"editor":[{"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,1,9]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0210384","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,1,9]]}}}